Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRXGet Rating) from a sell rating to a hold rating in a research report sent to investors on Monday.

Separately, Piper Sandler assumed coverage on Lexicon Pharmaceuticals in a research report on Friday, August 12th. They issued an overweight rating and a $10.00 price target for the company.

Lexicon Pharmaceuticals Trading Down 4.1 %

Shares of NASDAQ LXRX opened at $2.13 on Monday. The company has a quick ratio of 7.54, a current ratio of 7.54 and a debt-to-equity ratio of 0.17. The business has a fifty day simple moving average of $2.24 and a two-hundred day simple moving average of $2.32. The firm has a market cap of $401.99 million, a PE ratio of -3.44 and a beta of 1.36. Lexicon Pharmaceuticals has a twelve month low of $1.31 and a twelve month high of $5.22.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Integral Health Asset Management LLC bought a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter worth $558,000. Victory Capital Management Inc. grew its stake in Lexicon Pharmaceuticals by 76.8% during the 3rd quarter. Victory Capital Management Inc. now owns 20,433 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 8,873 shares during the last quarter. Teacher Retirement System of Texas purchased a new position in Lexicon Pharmaceuticals during the 3rd quarter worth $58,000. The Manufacturers Life Insurance Company purchased a new position in Lexicon Pharmaceuticals during the 3rd quarter worth $38,000. Finally, ProShare Advisors LLC grew its stake in Lexicon Pharmaceuticals by 24.2% during the 3rd quarter. ProShare Advisors LLC now owns 24,625 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,793 shares during the last quarter.

Lexicon Pharmaceuticals Company Profile

(Get Rating)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.

Further Reading

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.